# A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

> **NCT00170937** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 507 (—)

## Conditions studied

- METABOLIC SYNDROME
- HYPERTENSION
- PRE-HYPERTENSION

## Interventions

- **DRUG:** valsartan plus hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00170937
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 507 (—)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170937, "A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00170937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*